NGeneBio, a Korean company specializing in next-generation sequencing (NGS) precision diagnostics, has entered the Malaysian precision medicine market through a supply agreement with Sunway Medical Centre, one of Malaysia’s largest healthcare institutions. The initial supply includes NGeneBio’s cancer diagnostic solutions, HEMEaccuPanel DNA and HEMEaccuPanel RNA, which are used for blood cancer screening. The company plans to expand its offerings to include SOLIDaccuPanel for solid tumors and BRCAaccuPanel for breast and ovarian cancer diagnostics.
This expansion into Malaysia has been in preparation since early 2024 through a distribution agreement with SPD Scientific (M) Sdn Bhd, a subsidiary of Biomedia Holdings, a Singapore-based medical and laboratory equipment distributor with a strong presence in Southeast Asia. This partnership is seen as a strategic asset for NGeneBio’s global expansion, particularly in the Southeast Asian region.
The entry into the Malaysian market follows NGeneBio’s recent progress in Vietnam and Singapore, as well as additional contracts secured in December for its NGS precision diagnostic solutions in Vietnam and Thailand. CEO Choi Dae-chul emphasized the company’s commitment to strengthening ties with major medical institutions in Southeast Asia to establish NGeneBio as a leader in precision medicine.
This expansion aligns with NGeneBio’s broader strategy to become the leading NGS diagnostics provider in Southeast Asia by 2025. The company has been actively participating in international medical conferences and exhibitions to showcase its innovative products and technologies, including its automated disease genomics analysis software, NGeneAnalySys.
(Source: Korea Biomedical Review)
